Template:Dgfn2015 So xx:00 Molekulare Methoden, neuere
From HOP house of papers
(Difference between revisions)
Ossip Groth (Talk | contribs) |
Ossip Groth (Talk | contribs) m |
||
| (3 intermediate revisions by one user not shown) | |||
| Line 1: | Line 1: | ||
| − | == | + | ==So 08:45 Molekulare Methoden, neuere== |
| + | |||
| + | ===CRISPR/Cas9 – ein Quantensprung in der Gentechnik=== | ||
| + | [http://nephrologie.conference2web.com/users/7523 Schermer-B] | ||
{{tp|p=22745249|t=2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity |pdf=http://diyhpl.us/~bryan/papers2/paperbot/A%20Programmable%20Dual-RNAGuided%20DNA%20Endonuclease%20in%20Adaptive%20Bacterial%20Immunity.pdf|usr=|c=First description of the cc system}} | {{tp|p=22745249|t=2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity |pdf=http://diyhpl.us/~bryan/papers2/paperbot/A%20Programmable%20Dual-RNAGuided%20DNA%20Endonuclease%20in%20Adaptive%20Bacterial%20Immunity.pdf|usr=|c=First description of the cc system}} | ||
{{tp|p=24157548|t=2013. Genome engineering using the CRISPR-Cas9 system |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=24157548&pmc=3969860&ti=Genome%20engineering%20using%20the%20CRISPR-Cas9%20system|usr=}} | {{tp|p=24157548|t=2013. Genome engineering using the CRISPR-Cas9 system |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=24157548&pmc=3969860&ti=Genome%20engineering%20using%20the%20CRISPR-Cas9%20system|usr=}} | ||
| Line 8: | Line 11: | ||
{{utp|p=25908821|t=2015. Genome editing The mutagenic chain reaction: a method for converting heterozygous to homozygous mutations |pdf=http://www.sciencemag.org/content/348/6233/442.long|usr=}} | {{utp|p=25908821|t=2015. Genome editing The mutagenic chain reaction: a method for converting heterozygous to homozygous mutations |pdf=http://www.sciencemag.org/content/348/6233/442.long|usr=}} | ||
| − | == | + | ===miRNA als diagnostisches Werkzeug im klinischen Alltag?=== |
| + | [http://nephrologie.conference2web.com/users/7525 Lorenzen JM] | ||
| + | |||
| + | {{tp|p=18455518|t=2008. Lysophosphatidic acid and renal fibrosis |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=18455518&pmc=2577601&ti=Lysophosphatidic%20acid%20and%20renal%20fibrosis|usr=}} | ||
{{utp|p=21423249|t=2011. MicroRNAs as mediators and therapeutic targets in chronic kidney disease |pdf=http://www.nature.com/nrneph/journal/v7/n5/full/nrneph.2011.26.html|usr=}} | {{utp|p=21423249|t=2011. MicroRNAs as mediators and therapeutic targets in chronic kidney disease |pdf=http://www.nature.com/nrneph/journal/v7/n5/full/nrneph.2011.26.html|usr=}} | ||
{{utp|p=16258535|t=2005. Silencing of microRNAs in vivo with antagomirs |pdf=http://www.nature.com/nature/journal/v438/n7068/full/nature04303.html|usr=}} | {{utp|p=16258535|t=2005. Silencing of microRNAs in vivo with antagomirs |pdf=http://www.nature.com/nature/journal/v438/n7068/full/nature04303.html|usr=}} | ||
| Line 22: | Line 28: | ||
{{tp|p=22715378|t=2012. Circulating microRNAs are not eliminated by hemodialysis |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=22715378&pmc=3371001&ti=Circulating%20microRNAs%20are%20not%20eliminated%20by%20hemodialysis|usr=}} | {{tp|p=22715378|t=2012. Circulating microRNAs are not eliminated by hemodialysis |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=22715378&pmc=3371001&ti=Circulating%20microRNAs%20are%20not%20eliminated%20by%20hemodialysis|usr=}} | ||
| − | == | + | ===Translation of anti-fibrotic microRNA strategies into a mouse model of chronic allograft dysfunction=== |
| + | [http://nephrologie.conference2web.com/users/7524 Schauerte C] | ||
{{tp|p=18455518|t=2008. Lysophosphatidic acid and renal fibrosis |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=18455518&pmc=2577601&ti=Lysophosphatidic%20acid%20and%20renal%20fibrosis|usr=}} | {{tp|p=18455518|t=2008. Lysophosphatidic acid and renal fibrosis |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=18455518&pmc=2577601&ti=Lysophosphatidic%20acid%20and%20renal%20fibrosis|usr=}} | ||
?? ncb 2009... | ?? ncb 2009... | ||
{{tp|p=23131772|t=2012. MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=23131772&pmc=3541003&ti=MicroRNA%20sequence%20profiles%20of%20human%20kidney%20allografts%20with%20or%20without%20tubulointerstitial%20fibrosis|usr=}} | {{tp|p=23131772|t=2012. MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis |pdf=http://sm.kidney.de/epmc.php?ep=eu&pmid=23131772&pmc=3541003&ti=MicroRNA%20sequence%20profiles%20of%20human%20kidney%20allografts%20with%20or%20without%20tubulointerstitial%20fibrosis|usr=}} | ||
| − | == | + | ===Funktionelle Proteom-Analysen in der Nephrologie=== |
| + | [http://nephrologie.conference2web.com/users/7526 Rinschen M] | ||
| + | webcast not available | ||
| − | + | ?2014 nature au? | |
| − | + | ?2010 ncb coudhary/choudhary? | |
| − | + | {{tp|p=16641100|t=2006. Quantitative phosphoproteomics of vasopressin-sensitive renal cells: regulation of aquaporin-2 phosphorylation at two sites |pdf=http://www.pnas.org/content/103/18/7159.full.pdf|usr=}} | |
| − | + | {{tp|p=20139300|t=2010. Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells |pdf=http://www.pnas.org/content/107/8/3882.full.pdf|usr=}} | |
| − | + | {{tp|p=20713729|t=2010. Quantitative phosphoproteomic analysis reveals cAMP/vasopressin-dependent signaling pathways in native renal thick ascending limb cells |pdf=http://www.pnas.org/content/107/35/15653.full.pdf|usr=}} | |
| − | + | {{tp|p=24511133|t=2014. Phosphoproteomic analysis reveals regulatory mechanisms at the kidney filtration barrier |pdf=http://jasn.asnjournals.org/content/25/7/1509.full.pdf|usr=}} | |
| − | + | {{utp|p=25420462|t=2015. Comparative phosphoproteomic analysis of mammalian glomeruli reveals conserved podocin C-terminal phosphorylation as a determinant of slit diaphragm complex architecture |pdf=http://onlinelibrary.wiley.com/doi/10.1002/pmic.201400235/epdf|usr=}} | |
| − | + | {{tp|p=23438854|t=2013. The coming age of complete, accurate, and ubiquitous proteomes |pdf=http://www.cell.com/molecular-cell/pdf/S1097-2765(13)00093-2.pdf|usr=}} | |
| − | + | {{tp|p=23201125|t=2013. A map of general and specialized chromatin readers in mouse tissues generated by label-free interaction proteomics |pdf=http://www.cell.com/molecular-cell/pdf/S1097-2765(12)00907-0.pdf|usr=}} | |
| − | {{tp|p= | + | {{tp|p=24573087|t=2014. Label-free quantitative proteomic analysis of the YAP/TAZ interactome |pdf=http://ajpcell.physiology.org/content/ajpcell/306/9/C805.full.pdf|usr=}} |
| + | {{utp|p=24051958|t=2013. Large-scale identification of ubiquitination sites by mass spectrometry |pdf=http://www.nature.com/nprot/journal/v8/n10/full/nprot.2013.120.html|usr=}} | ||
Latest revision as of 06:44, 22 September 2015
Contents |
So 08:45 Molekulare Methoden, neuere
CRISPR/Cas9 – ein Quantensprung in der Gentechnik
| Journal article, free access (Hinweis: First description of the cc system) |
| GET 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity Extract PDF direct |
| Journal article, free access |
| GET 2013. Genome engineering using the CRISPR-Cas9 system Extract PDF direct |
| Journal article, free access |
| GET 2013. Genome engineering using the CRISPR-Cas9 system Extract PDF direct |
| Journal article, free access (Hinweis: Major bioethical document) |
| GET 2015. CRISPR, the disruptor Extract PDF direct |
| Journal article, free access |
| GET 2015. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes Extract PDF direct |
| Journal Paper, restricted access |
| GET 2015. BIOSAFETY Safeguarding gene drive experiments in the laboratory Extract PDF direct |
| Journal Paper, restricted access |
| GET 2015. Genome editing The mutagenic chain reaction: a method for converting heterozygous to homozygous mutations Extract PDF direct |
miRNA als diagnostisches Werkzeug im klinischen Alltag?
| Journal article, free access |
| GET 2008. Lysophosphatidic acid and renal fibrosis Extract PDF direct |
| Journal Paper, restricted access |
| GET 2011. MicroRNAs as mediators and therapeutic targets in chronic kidney disease Extract PDF direct |
| Journal Paper, restricted access |
| GET 2005. Silencing of microRNAs in vivo with antagomirs Extract PDF direct |
| Journal article, free access |
| GET 2009. MicroRNA expression profiles predictive of human renal allograft status Extract PDF direct |
| Journal article, free access |
| GET 2012. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways Extract PDF direct |
| Journal article, free access |
| GET 2014. MicroRNA-24 antagonism prevents renal ischemia reperfusion injury Extract PDF direct |
| Journal article, free access |
| GET 2012. Circulating and urinary microRNAs in kidney disease Extract PDF direct |
| Journal article, free access |
| GET 2014. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy Extract PDF direct |
| Journal article, free access |
| GET 2011. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma Extract PDF direct |
| Journal article, free access |
| GET 2011. Urinary miR-210 as a mediator of acute T-cell mediated rejection in renal allograft recipients Extract PDF direct |
| Journal article, free access |
| GET 2012. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells Extract PDF direct |
| Journal article, free access |
| GET 2011. Circulating miR-210 predicts survival in critically ill patients with acute kidney injury Extract PDF direct |
| Journal article, free access |
| GET 2012. Circulating microRNAs are not eliminated by hemodialysis Extract PDF direct |
Translation of anti-fibrotic microRNA strategies into a mouse model of chronic allograft dysfunction
| Journal article, free access |
| GET 2008. Lysophosphatidic acid and renal fibrosis Extract PDF direct |
?? ncb 2009...
| Journal article, free access |
| GET 2012. MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis Extract PDF direct |
Funktionelle Proteom-Analysen in der Nephrologie
Rinschen M webcast not available
?2014 nature au? ?2010 ncb coudhary/choudhary?
| Journal article, free access |
| GET 2006. Quantitative phosphoproteomics of vasopressin-sensitive renal cells: regulation of aquaporin-2 phosphorylation at two sites Extract PDF direct |
| Journal article, free access |
| GET 2010. Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells Extract PDF direct |
| Journal article, free access |
| GET 2010. Quantitative phosphoproteomic analysis reveals cAMP/vasopressin-dependent signaling pathways in native renal thick ascending limb cells Extract PDF direct |
| Journal article, free access |
| GET 2014. Phosphoproteomic analysis reveals regulatory mechanisms at the kidney filtration barrier Extract PDF direct |
| Journal Paper, restricted access |
| GET 2015. Comparative phosphoproteomic analysis of mammalian glomeruli reveals conserved podocin C-terminal phosphorylation as a determinant of slit diaphragm complex architecture Extract PDF direct |
| Journal article, free access |
| GET 2013. The coming age of complete, accurate, and ubiquitous proteomes Extract PDF direct |
| Journal article, free access |
| GET 2013. A map of general and specialized chromatin readers in mouse tissues generated by label-free interaction proteomics Extract PDF direct |
| Journal article, free access |
| GET 2014. Label-free quantitative proteomic analysis of the YAP/TAZ interactome Extract PDF direct |
| Journal Paper, restricted access |
| GET 2013. Large-scale identification of ubiquitination sites by mass spectrometry Extract PDF direct |
